Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant for solid-organ transplant recipients and patients with autoimmune disorders. We report a case of lymphoedema, a rare complication of sirolimus, and discuss the mechanism of drug action, the adverse effects and the challenges of treating a kidney transplant recipient with this complication in a resource-limited environment. Lymphoedema is a rare complication of sirolimus, and the mechanisms are not completely understood; however, early recognition can prevent permanent disfiguration. This case highlights the need for early recognition of adverse drug effects and further research into their pathophysiology and management.
CITATION STYLE
Motse, K. G., & Mashabane, M. J. (2016). Sirolimus-induced lymphoedema. South African Medical Journal, 106(9), 886–887. https://doi.org/10.7196/SAMJ.2016.v106i9.10636
Mendeley helps you to discover research relevant for your work.